Cargando…
Compliance with the Updated BASHH Recurrent Vulvovaginal Candidiasis Guidelines Improves Patient Outcomes
Recurrent vulvovaginal candidiasis (RVVC) is a debilitating, chronic condition that affects over 138 million (6%) women of reproductive age annually. We performed a retrospective audit of RVVC referrals to our tertiary care Candida clinic to evaluate the impact of the significantly updated British A...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503580/ https://www.ncbi.nlm.nih.gov/pubmed/36135648 http://dx.doi.org/10.3390/jof8090924 |
_version_ | 1784795999318835200 |
---|---|
author | Brown, Lottie Chamula, Mathilde Weinberg, Sharon Jbueen, Frakinda Rautemaa-Richardson, Riina |
author_facet | Brown, Lottie Chamula, Mathilde Weinberg, Sharon Jbueen, Frakinda Rautemaa-Richardson, Riina |
author_sort | Brown, Lottie |
collection | PubMed |
description | Recurrent vulvovaginal candidiasis (RVVC) is a debilitating, chronic condition that affects over 138 million (6%) women of reproductive age annually. We performed a retrospective audit of RVVC referrals to our tertiary care Candida clinic to evaluate the impact of the significantly updated British Association of Sexual Health and HIV (BASHH) 2019 vulvovaginal candidiasis guidelines on patient outcomes, the principles of which were implemented at our centre at the onset of the guideline revision process in 2017. A total of 78 women referred with suspected RVVC in 2017–2020 were included. Their mean symptom duration prior to referral was 6.7 years. RVVC was the definitive diagnosis in 73% of cases. In the 27% of patients without RVVC, the most common diagnoses were acute VVC (29%), vulval eczema (14%), dry skin (14%) and vulvodynia (10%). Of those with RVVC, 60% were diagnosed with an additional diagnosis, most commonly vulval eczema or vulvodynia. Only 12% of women had been counselled on appropriate vulval skin care, the mainstay of RVVC management. Long-term antifungal suppression was initiated in 68% of women. Azole-resistant Candida, for which there is no licensed treatment available in the UK, was identified in 23% of women with RVVC. In the follow-up, 82% of patients reported good control of symptoms using antifungal suppression therapy and recommended skin care, 16% had partial symptom control with some “flare-ups” responding to treatment, none reported poor control and for 2% this information was not available. RVVC-related morbidity can be reduced by following the principles outlined in the BASHH guidelines. |
format | Online Article Text |
id | pubmed-9503580 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95035802022-09-24 Compliance with the Updated BASHH Recurrent Vulvovaginal Candidiasis Guidelines Improves Patient Outcomes Brown, Lottie Chamula, Mathilde Weinberg, Sharon Jbueen, Frakinda Rautemaa-Richardson, Riina J Fungi (Basel) Article Recurrent vulvovaginal candidiasis (RVVC) is a debilitating, chronic condition that affects over 138 million (6%) women of reproductive age annually. We performed a retrospective audit of RVVC referrals to our tertiary care Candida clinic to evaluate the impact of the significantly updated British Association of Sexual Health and HIV (BASHH) 2019 vulvovaginal candidiasis guidelines on patient outcomes, the principles of which were implemented at our centre at the onset of the guideline revision process in 2017. A total of 78 women referred with suspected RVVC in 2017–2020 were included. Their mean symptom duration prior to referral was 6.7 years. RVVC was the definitive diagnosis in 73% of cases. In the 27% of patients without RVVC, the most common diagnoses were acute VVC (29%), vulval eczema (14%), dry skin (14%) and vulvodynia (10%). Of those with RVVC, 60% were diagnosed with an additional diagnosis, most commonly vulval eczema or vulvodynia. Only 12% of women had been counselled on appropriate vulval skin care, the mainstay of RVVC management. Long-term antifungal suppression was initiated in 68% of women. Azole-resistant Candida, for which there is no licensed treatment available in the UK, was identified in 23% of women with RVVC. In the follow-up, 82% of patients reported good control of symptoms using antifungal suppression therapy and recommended skin care, 16% had partial symptom control with some “flare-ups” responding to treatment, none reported poor control and for 2% this information was not available. RVVC-related morbidity can be reduced by following the principles outlined in the BASHH guidelines. MDPI 2022-08-30 /pmc/articles/PMC9503580/ /pubmed/36135648 http://dx.doi.org/10.3390/jof8090924 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Brown, Lottie Chamula, Mathilde Weinberg, Sharon Jbueen, Frakinda Rautemaa-Richardson, Riina Compliance with the Updated BASHH Recurrent Vulvovaginal Candidiasis Guidelines Improves Patient Outcomes |
title | Compliance with the Updated BASHH Recurrent Vulvovaginal Candidiasis Guidelines Improves Patient Outcomes |
title_full | Compliance with the Updated BASHH Recurrent Vulvovaginal Candidiasis Guidelines Improves Patient Outcomes |
title_fullStr | Compliance with the Updated BASHH Recurrent Vulvovaginal Candidiasis Guidelines Improves Patient Outcomes |
title_full_unstemmed | Compliance with the Updated BASHH Recurrent Vulvovaginal Candidiasis Guidelines Improves Patient Outcomes |
title_short | Compliance with the Updated BASHH Recurrent Vulvovaginal Candidiasis Guidelines Improves Patient Outcomes |
title_sort | compliance with the updated bashh recurrent vulvovaginal candidiasis guidelines improves patient outcomes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503580/ https://www.ncbi.nlm.nih.gov/pubmed/36135648 http://dx.doi.org/10.3390/jof8090924 |
work_keys_str_mv | AT brownlottie compliancewiththeupdatedbashhrecurrentvulvovaginalcandidiasisguidelinesimprovespatientoutcomes AT chamulamathilde compliancewiththeupdatedbashhrecurrentvulvovaginalcandidiasisguidelinesimprovespatientoutcomes AT weinbergsharon compliancewiththeupdatedbashhrecurrentvulvovaginalcandidiasisguidelinesimprovespatientoutcomes AT jbueenfrakinda compliancewiththeupdatedbashhrecurrentvulvovaginalcandidiasisguidelinesimprovespatientoutcomes AT rautemaarichardsonriina compliancewiththeupdatedbashhrecurrentvulvovaginalcandidiasisguidelinesimprovespatientoutcomes |